YHB Investment Advisors Inc. grew its position in Becton Dickinson and Co (NYSE:BDX) by 5.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,329 shares of the medical instruments supplier’s stock after buying an additional 1,751 shares during the quarter. Becton Dickinson and accounts for 1.3% of YHB Investment Advisors Inc.’s holdings, making the stock its 22nd largest holding. YHB Investment Advisors Inc.’s holdings in Becton Dickinson and were worth $8,431,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the business. TRUE Private Wealth Advisors purchased a new stake in shares of Becton Dickinson and during the 2nd quarter worth $25,000. Allworth Financial LP lifted its stake in shares of Becton Dickinson and by 386.4% during the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 85 shares during the last quarter. Hexavest Inc. purchased a new stake in shares of Becton Dickinson and during the 2nd quarter worth $28,000. Lipe & Dalton purchased a new stake in shares of Becton Dickinson and during the 2nd quarter worth $28,000. Finally, CX Institutional purchased a new stake in shares of Becton Dickinson and during the 3rd quarter worth $31,000. Institutional investors and hedge funds own 84.23% of the company’s stock.
Shares of NYSE:BDX opened at $252.68 on Tuesday. The business’s 50-day moving average is $253.77 and its 200 day moving average is $246.00. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $264.74. The firm has a market capitalization of $68.26 billion, a P/E ratio of 22.95, a P/E/G ratio of 1.62 and a beta of 1.12. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67.
The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date was Friday, September 6th. Becton Dickinson and’s dividend payout ratio is presently 27.97%.
A number of equities research analysts recently weighed in on BDX shares. Wells Fargo & Co upped their price objective on Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley upped their target price on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 16th. Piper Jaffray Companies reduced their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Finally, Raymond James upped their target price on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research report on Friday, June 28th. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Buy” and an average target price of $266.55.
In other news, CEO Vincent A. Forlenza sold 11,532 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the transaction, the chief executive officer now directly owns 218,671 shares of the company’s stock, valued at $56,937,554.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Alexandre Conroy sold 9,829 shares of the stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $255.06, for a total value of $2,506,984.74. Following the completion of the transaction, the executive vice president now directly owns 16,535 shares in the company, valued at $4,217,417.10. The disclosure for this sale can be found here. Insiders sold 37,249 shares of company stock worth $9,616,803 over the last three months. Corporate insiders own 0.12% of the company’s stock.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Options Trading – Understanding Strike Price
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.